Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

The Journal of Clinical Investigation
Elizabeth Buchbinder, F Stephen Hodi

Abstract

The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation by costimulatory signals. Fully human monoclonal antibodies targeting CTLA-4 have been shown to increase T cell function and antitumor responses in patients with advanced metastatic melanoma. Responses observed with such immune checkpoint therapy can follow a different pattern from that seen with cytotoxic chemotherapy or targeted therapy and may continue after therapy is discontinued. In addition, the toxicities that are associated with anti-CTLA-4 therapy may differ from those of conventional therapies and consist of inflammatory events in parts of the body that do not contain cancerous cells. Early recognition of these inflammatory events and intervention is important, and the identification of predictive biomarkers continues to be an unfulfilled need in the field of immunotherapy. Combinatorial approaches with targeted therapies, radiation therapy, chemotherapy, or other immune checkpoint agonists/antagonists have the potential to increase the efficacy of CTLA-4 blockade.

References

Sep 11, 1970·Science·P Bretscher, M Cohn
Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
Oct 1, 1995·Current Opinion in Immunology·J P AllisonD R Leach
Mar 22, 1996·Science·D R LeachJ P Allison
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·E D KwonJ P Allison
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Mar 26, 2002·Nature Reviews. Immunology·Arlene H Sharpe, Gordon J Freeman
Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Nov 25, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tibor KelerAlan Korman
May 12, 2004·Current Opinion in Immunology·Richard A KroczekAndreas Hutloff
Oct 18, 2005·Molecular and Cellular Biology·Richard V ParryJames L Riley
Jun 27, 2006·Journal of Immunotherapy·Ajay V MakerSteven A Rosenberg
Aug 16, 2006·The New England Journal of Medicine·Arlene H Sharpe, Abul K Abbas
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric J SmallJames P Allison
Jul 11, 2008·Immunological Reviews·Kenneth J Scalapino, David I Daikh
Sep 2, 2008·Immunological Reviews·Brian T Fife, Jeffrey A Bluestone
Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lawrence Fong, Eric J Small
Oct 11, 2008·Science·Kajsa WingShimon Sakaguchi
Nov 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberEvan Hersh
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis H CamachoAntoni Ribas
Mar 25, 2009·Journal of Immunotherapy·Vincenzo Bronte, Simone Mocellin
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Feb 12, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J O'DayJ D Wolchok
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Nov 16, 2010·Seminars in Oncology·Luana CalabròMichele Maio
Jan 12, 2011·Annual Review of Immunology·Matthew D VeselyMark J Smyth
Apr 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven A RosenbergMark E Dudley
May 24, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Poulam M PatelUNKNOWN EORTC Melanoma Group
Jun 1, 2011·Cancer Immunology, Immunotherapy : CII·Isabel PoschkeRolf Kiessling
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Dec 8, 2011·Cancer Immunology, Immunotherapy : CII·Rui-Ru JiVafa Shahabi
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter A PrietoGiao Q Phan

❮ Previous
Next ❯

Citations

Jul 28, 2016·Human Vaccines & Immunotherapeutics·Mohammed DanyDirk Elston
Dec 21, 2016·Immunotherapy·Pierpaolo CorrealePierosandro Tagliaferri
Dec 28, 2016·Cell Research·Rong-Fu Wang, Helen Y Wang
Feb 7, 2017·Vaccines·Derek C MacallanBecca Asquith
Apr 8, 2017·Molecular Pharmaceutics·Emily B EhlerdingWeibo Cai
Apr 4, 2017·Immunology and Allergy Clinics of North America·Santhosh KumarAnne-Marie Irani
May 27, 2017·Cancer Investigation·Giorgos BamiasHelen Gogas
Jul 13, 2017·Asia-Pacific Journal of Clinical Oncology·Kate RobertsBrett Gm Hughes
May 4, 2018·The Neurologist·Michael W Ruff, Michelle L Mauermann
Aug 23, 2017·Expert Opinion on Biological Therapy·Mauro Alaibac
Aug 30, 2018·Current Opinion in Gastroenterology·Spyros I Siakavellas, Giorgos Bamias
Apr 3, 2016·Journal of Hematology & Oncology·Bo LiYangqiu Li
Feb 18, 2017·Frontiers in Immunology·Qi ZhangYongsheng Li
Jun 20, 2017·Immunology·Louise M C Webb, Michelle A Linterman
Apr 26, 2018·Frontiers in Neuroscience·Diana AmanteaGiacinto Bagetta
Sep 3, 2019·Frontiers in Genetics·Zhenhua ZhangMengji Lu
Jun 22, 2016·Current Allergy and Asthma Reports·Sarah E HenricksonMildred Kwan
Sep 11, 2019·Nature Reviews. Urology·Anna K SchneiderLaurent Derré
Jul 12, 2018·Acta Pharmacologica Sinica·Jiu-Cheng ZhangHua Zhu
Jan 7, 2020·Therapeutic Advances in Endocrinology and Metabolism·Edson NogueiraDaniel L Morganstein
Sep 2, 2015·The Journal of Clinical Investigation·Yiping Yang
Aug 1, 2016·Hepatic Oncology·Christopher E JensenPaula A Bonilla-Reyes
Oct 18, 2019·Nature Reviews. Clinical Oncology·James T YurkovichLeroy Hood
Jun 11, 2019·Seminars in Ophthalmology·Larissa A HabibMichael K Yoon
Jun 30, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhenhua RenYang-Xin Fu
Dec 21, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Deepak PerumalSamir Parekh

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02141542
NCT02369874
NCT02352948
NCT02261220
NCT02210117
NCT02231749
NCT02089685
NCT01689974
NCT02239900
NCT02107755

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
April K S Salama, F Stephen Hodi
Clinical Therapeutics
Elizabeth Buchbinder, David F McDermott
Cancer Immunology, Immunotherapy : CII
Yago Pico de CoañaRolf Kiessling
© 2021 Meta ULC. All rights reserved